Collegium’s Q1 2026 Playbook: JORNAY PM Powers Growth as AZSTARYS Enters the Ring

Quarterly highlights you can actually annotate in the margins

Collegium Pharmaceutical, Inc. (ticker: COLL) reported its first-quarter 2026 results for the quarter ended March 31, 2026. The topline looks sturdy: net revenues of $193.5 million, up 9% year over year, with the company’s ADHD flagship, JORNAY PM, contributing $38.9 million in net revenue—an impressive 36% rise versus the prior year. The Pain Portfolio also kept the lights on, generating $154.6 million in net revenue, up 4% YoY. Notably, the company ended the quarter with cash, cash equivalents and marketable securities totaling $421.8 million, a liquidity line that will matter as management gears up for the AZSTARYS integration. The company reaffirmed its full-year 2026 guidance, a statement that serves more as a compass than a guarantee in the volatility of pharma timing.

On the earnings front, the release rolled out a clean revenue narrative but did not disclose a stand-alone EPS figure in the press materials tied to this quarter. As a result, investors will be watching for an EPS number and how it stacks up against consensus estimates. In the language of market analysts, that means an implicit focus on EPS consensus and whether there is an earnings surprise relative to expectations. In other words, the headline generates a revenue story; the real test will be whether the earnings line follows or disappoints expectations when the company files or speaks on the call.

AZSTARYS acquisition: a growth engine or a financing chess move?

The big strategic event is Collegium’s plan to acquire AZSTARYS from Corium Therapeutics for $650 million in cash, with potential milestone payments up to $135 million. Management expects the deal to close in the second quarter of 2026 and to be immediately accretive to adjusted EBITDA. By any standard, this is a substantial bet on accelerating ADHD growth and diversifying beyond the JORNAY PM core.

From a financing perspective, using $650 million in cash implies near-term liquidity considerations. Collegium ended Q1 with roughly $421.8 million of liquidity on hand, which raises questions about the funding mix—will the company deplete cash on hand and/or supplement with debt or other financing? If financed primarily with cash, the balance sheet will bear the burden of the near-term cash outlay before any cash inflows from AZSTARYS milestones. If additional debt or equity enters the mix, investors will want to see how that affects the EPS trajectory, debt covenants, and the potential for future equity issuance to fund growth. In any case, the assertion that the deal will be EBITDA accretive hinges on the performance of AZSTARYS and the efficiency of post-close integration.

AZSTARYS is described as highly complementary and differentiated, a label that pharma executives like to throw around when describing pipelines that “fit” a portfolio. The near-term read is that AZSTARYS could broaden Collegium’s ADHD revenue runway into the late 2030s, a leap that also carries integration risk, potential milestone variability, and the usual post-merger productivity puzzles—like aligning sales forces and marketing strategies across products with overlapping indications and payer dynamics.

For investors and sector peers, the AZSTARYS move underscores a continued preference for bolt-on acquisitions to accelerate growth rather than relying solely on internal R&D pipelines. The risk is that the incremental revenue stream is tied to a big cash outlay and the success of integration milestones; the reward is a more diversified ADHD portfolio and a potentially steadier revenue stream as AZSTARYS scales.

Outlook and guidance: a forecast to test

Collegium reaffirmed its 2026 guidance for the current business, signaling confidence in the core franchise even as it leans into the AZSTARYS expansion. The company framed the organization as positioned to capitalize on leading growth in ADHD and a solid pain portfolio, while projecting the late-2020s revenue trajectory to be supported by AZSTARYS contributions post-close.

Two forward-looking questions for the Street loom large:

• Revenue forecast: Will the AZSTARYS addition lift the company’s revenue trajectory enough to offset any near-term dilution from the acquisition financing and amortization of intangibles?
• EPS and earnings surprise risk: Without a disclosed EPS figure in the press release, how will the report stack up against EPS consensus once the company provides more detail on margins, milestones, and integration costs?

The conference call, scheduled for today at 8:00 a.m. ET, will be the venue where management translates the headline numbers into a fuller narrative—particularly around how AZSTARYS will influence adjusted EBITDA and the long-term revenue forecast.

Leadership voices: momentum, caution, and the road ahead

Vikram Karnani, President and Chief Executive Officer, framed Q1 as a demonstration of progress on 2026 strategic priorities—most notably the momentum behind JORNAY PM and the anticipated integration of AZSTARYS. The tone suggested that the ADHD portfolio, supported by expanded sales reach, is driving near-term growth, while the AZSTARYS transaction represents a meaningful step toward a broader, differentiated ADHD franchise.

Colleen Tupper, Chief Financial Officer, emphasized Collegium’s strong liquidity position and its ability to deploy capital strategically. Her remarks pointed to the finance function as enabling continued execution on the azimuth of growth, including the AZSTARYS transaction and related profitability objectives. Taken together, the executives painted a picture of disciplined expansion—growth through product leadership and selective acquisitions, backed by a robust balance sheet.

ADHD highlights: the backbone of growth

• JORNAY PM net revenue: $38.9 million in the 2026 Quarter, up 36% year over year.
• Prescriptions for JORNAY PM: over 206,000 in the 2026 Quarter; prescribers around 30,000, up ~17% YoY.
• AZSTARYS: acquisition expected to close in Q2 2026; addition aimed at expanding the ADHD portfolio with growth potential and a diversified revenue base.

These numbers frame the company’s core growth runway: a high-frequency, physician-adopted product, supported by a growing prescriber base, and a new asset that could meaningfully boost revenue scale if integration executes smoothly. It’s a reminder that the ADHD market remains a focal growth vector for Collegium and for peers chasing similar specialty pharma niches.

Analysis: what this signals for COLL and its peers

From a strategic lens, the combination of a growing JORNAY PM franchise and the AZSTARYS acquisition signals a two-pronged approach: (1) reinforce near-term revenue streams through a best-in-class ADHD portfolio, and (2) anchor future growth with a larger, diversified ADHD pipeline. If the AZSTARYS deal closes on time and delivers the expected EBITDA acceleration, Collegium could shift its multiple- expansion story from “steady organic growth” toward “growth through selective, high-return acquisitions.”

For sector peers, the implications are twofold. First, the ADHD landscape remains ripe for consolidation, as players seek to broaden therapeutic offerings and accelerate sales force efficiency. Second, the market will scrutinize capital discipline—how much cash is truly available for tuck-in acquisitions, how milestones are priced, and how post-close synergies are realized. In other words, the rubric for the quarter’s success will extend beyond the revenue line to include EBITDA, cash flow, and the quality of earnings relative to consensus expectations.

Investors will likely watch two levers: (a) the evolution of the revenue forecast once AZSTARYS contributes post-close, and (b) the EPS trajectory given the near-term financing and potential amortization costs. An earnings surprise, in this context, would more likely come from better-than-expected EBITDA or margin improvements rather than a dramatic swing in the headline revenue figure alone. Still, the market will price the story as a combined growth-and-acquisition thesis, which can be sensitive to execution risk and milestones timing.

Bottom line

COLL continues to show a compelling growth narrative centered on JORNAY PM and its ADHD portfolio, while the AZSTARYS deal opens a new chapter with the potential to lift the company into a larger growth trajectory. The near-term questions—how the deal is financed, how quickly EBITDA accelerates post-close, and how EPS and the revenue forecast converge—will determine whether the stock re-rates higher or remains tethered to execution risk. In the meantime, the market gets a cleaner signal of where the ADHD value chain might head next: more scale, more diversified products, and more opportunities to buy growth rather than wait for it to sprout from pipelines alone.

Investor takeaway: COLL’s path depends on execution as much as ambition. The stock ticker COLL will trade on the story of how quickly AZSTARYS can be harnessed to accelerate growth, how the company manages its cash and financing, and whether the early 2026 optimism translates into a durable earnings trajectory that aligns with EPS consensus and a credible revenue forecast.